A Signaling Polypeptide Derived from an Innate Immune Adaptor Molecule Can Be Harnessed as a New Class of Vaccine Adjuvant

  • Kobiyama K
  • Takeshita F
  • Ishii K
  • et al.
18Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Modulation of intracellular signaling using cell-permeable polypeptides is a promising technology for future clinical applications. To develop a novel approach to activate innate immune signaling by synthetic polypeptides, we characterized several different polypeptides derived from the caspase recruitment domain (CARD) of IFN-β promoter stimulator 1, each of which localizes to a different subcellular compartment. Of particular interest was, N′-CARD, which consisted of the nuclear localization signal of histone H2B and the IFN-β promoter stimulator 1CARD and which localized to the nucleus. This polypeptide led to a strong production of type I IFNs and molecular and genetic analyses showed that nuclear DNA helicase II is critically involved in this response. N′-CARD polypeptide fused to a protein transduction domain (N′-CARD-PTD) readily transmigrated from the outside to the inside of the cell and triggered innate immune signaling. Administration of N′-CARD-PTD polypeptide elicited production of type I IFNs, maturation of bone marrow-derived dendritic cells, and promotion of vaccine immunogenicity by enhancing Ag-specific Th1-type immune responses, thereby protecting mice from lethal influenza infection and from outgrowth of transplanted tumors in vivo. Thus, our results indicate that the N′-CARD-PTD polypeptide belongs to a new class of vaccine adjuvant that directly triggers intracellular signal transduction by a distinct mechanism from those engaged by conventional vaccine adjuvants, such as TLR ligands.

Cite

CITATION STYLE

APA

Kobiyama, K., Takeshita, F., Ishii, K. J., Koyama, S., Aoshi, T., Akira, S., … Okuda, K. (2009). A Signaling Polypeptide Derived from an Innate Immune Adaptor Molecule Can Be Harnessed as a New Class of Vaccine Adjuvant. The Journal of Immunology, 182(3), 1593–1601. https://doi.org/10.4049/jimmunol.182.3.1593

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free